Glucopyranosyl lipid adjuvant (gla), a synthetic tlr4 agonist, promotes potent systemic and mucosal responses to intranasal immunization with hivgp140

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Arias, Mauricio A ^a   van Roey, Griet A ^a   Tregoning, John S ^a,b   Moutaftsi, Magdalini ^c   Coler, Rhea N ^c   Windish, Hillarie P ^c   Reed, Steven G ^c   Carter, Darrick ^c   Shattock, Robin J ^a,b  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c Infectious Diseases Research Institute (IDRI)   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; ANTIGEN; CHITOSAN; GLUCOPYRANOSYL LIPID ADJUVANT; GLYCOPROTEIN GP 140; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; RESIQUIMOD; TOLL LIKE RECEPTOR 4 AGONIST; TOLL LIKE RECEPTOR 7 AGONIST; TOLL LIKE RECEPTOR 8 AGONIST; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; EMULSION; FEMALE; GENITAL SYSTEM; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGLOBULIN BLOOD LEVEL; MOUSE; MUCOSAL IMMUNITY; NASAL LAVAGE; NONHUMAN; SYSTEMIC IMMUNE RESPONSE; TH17 CELL; TH2 CELL; UPPER RESPIRATORY TRACT; UROGENITAL SYSTEM; VAGINA IMMUNE RESPONSE; VAGINAL LAVAGE;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; FEMALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NASAL MUCOSA; TOLL-LIKE RECEPTOR 4;

MUS;

EID: 84864069831     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0041144     Document Type: Article

References (50)

1. Barnett SW, Srivastava IK, Kan E, Zhou F, Goodsell A, et al. (2008) Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope. AIDS 22: 339-348.
2. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, et al. (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361: 2209-2220.
3. Gilbert PB, Peterson ML, Follmann D, Hudgens MG, Francis DP, et al. (2005) Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis 191: 666-677.
4. Haynes BF, Shattock RJ, (2008) Critical issues in mucosal immunity for HIV-1 vaccine development. J Allergy Clin Immunol 122: 3-9. S0091-6749(08)00725-2 [pii];10.1016/j.jaci.2008.03.036 [doi].
5. Mascola JR, Montefiori DC, (2010) The Role of Antibodies in HIV Vaccines. Ann Rev Immunol 28: 413-444.
6. Nabel GJ, Kwong PD, Mascola JR, (2011) Progress in the rational design of an AIDS vaccine. Philos Trans R Soc Lond B Biol Sci 366: 2759-2765. 366/1579/2759 [pii];10.1098/rstb.2011.0096 [doi].
7. Koff WC, (2011) HIV vaccine development: Challenges and opportunities towards solving the HIV vaccine-neutralizing antibody problem. Vaccine. S0264-410X(11)01781-6 [pii];10.1016/j.vaccine.2011.11.014 [doi].
8. Willey S, Aasa-Chapman MM, (2008) Humoral immunity to HIV-1: neutralisation and antibody effector functions. Trends Microbiol 16: 596-604. S0966-842X(08)00220-5 [pii];10.1016/j.tim.2008.08.008 [doi].
9. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, et al. (2012) Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial. New England Journal of Medicine 366: 1275-1286.
10. Kemp TJ, García-Piñeres A, Falk RT, Poncelet S, Dessy F, et al. (2008) Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women. Vaccine 26: 3608-3616.
11. Neutra MR, Kozlowski PA, (2006) Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 6: 148-158. nri1777 [pii];10.1038/nri1777 [doi].
12. Lewis DJ, Fraser CA, Mahmoud AN, Wiggins RC, Woodrow M, et al. (2011) Phase I Randomised Clinical Trial of an HIV-1CN54, Clade C, Trimeric Envelope Vaccine Candidate Delivered Vaginally. PLoS ONE 6: e25165.
13. Cranage MP, Fraser CA, Cope A, McKay PF, Seaman MS, et al. (2011) Antibody responses after intravaginal immunisation with trimeric HIV-1CN54 clade C gp140 in Carbopol gel are augmented by systemic priming or boosting with an adjuvanted formulation. Vaccine 29: 1421-1430.
14. Holmgren J, Czerkinsky C, (2005) Mucosal immunity and vaccines. Nat Med 11: S45-S53. nm1213 [pii];10.1038/nm1213 [doi].
15. Kozlowski PA, Williams SB, Lynch RM, Flanigan TP, Patterson RR, et al. (2002) Differential induction of mucosal and systemic antibody responses in women after nasal, rectal, or vaginal immunization: influence of the menstrual cycle. J Immunol 169: 566-574.
16. Lambrecht BN, Kool M, Willart MA, Hammad H, (2009) Mechanism of action of clinically approved adjuvants. Curr Opin Immunol 21: 23-29. S0952-7915(09)00008-9 [pii];10.1016/j.coi.2009.01.004 [doi].
17. Di TA, Saletti G, Pizza M, Rappuoli R, Dougan G, et al. (1996) Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant. Infect Immun 64: 974-979.
18. Rudin A, Riise GC, Holmgren J, (1999) Antibody responses in the lower respiratory tract and male urogenital tract in humans after nasal and oral vaccination with cholera toxin B subunit. Infect Immun 67: 2884-2890.
19. Couch RB, (2004) Nasal vaccination, Escherichia coli enterotoxin, and Bell's palsy. N Engl J Med 350: 860-861.
20. Lewis DJ, Huo Z, Barnett S, Kromann I, Giemza R, et al. (2009) Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS ONE 4: e6999. 10.1371/journal.pone.0006999 [doi].
21. Duthie MS, Windish HP, Fox CB, Reed SG, (2011) Use of defined TLR ligands as adjuvants within human vaccines. Immunol Rev 239: 178-196.
22. Garcon N, Van MM, (2011) Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems. Expert Rev Vaccines 10: 471-486. 10.1586/erv.11.29 [doi].
23. Wiley SR, Raman VS, Desbien A, Bailor HR, Bhardwaj R, et al. (2011) Targeting TLRs expands the antibody repertoire in response to a malaria vaccine. Sci Transl Med 3: 93ra69. 3/93/93ra69 [pii];10.1126/scitranslmed.3002135 [doi].
24. Reed SG, Bertholet S, Coler RN, Friede M, (2009) New horizons in adjuvants for vaccine development. Trends Immunol 30: 23-32.
25. Takayama K, Qureshi N, Ribi E, Cantrell JL, (1984) Separation and characterization of toxic and nontoxic forms of lipid A. Rev Infect Dis 6: 439-443.
26. Baldrick P, Richardson D, Elliott G, Wheeler AW, (2002) Safety evaluation of monophosphoryl lipid A (MPL): an immunostimulatory adjuvant. Regul Toxicol Pharmacol 35: 398-413.
27. Coler RN, Bertholet S, Moutaftsi M, Guderian JA, Windish HP, et al. (2011) Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLoS ONE 6: e16333. 10.1371/journal.pone.0016333 [doi].
28. Anderson RC, Fox CB, Dutill TS, Shaverdian N, Evers TL, et al. (2010) Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations. Colloids Surf B Biointerfaces 75: 123-132.
29. Johnson DA, Sowell CG, Johnson CL, Livesay MT, Keegan DS, et al. (1999) Synthesis and biological evaluation of a new class of vaccine adjuvants: aminoalkyl glucosaminide 4-phosphates (AGPs). Bioorg Med Chem Lett 9: 2273-2278.
30. Su L, Graf M, Zhang Y, Von BH, Xing H, et al. (2000) Characterization of a virtually full-length human immunodeficiency virus type 1 genome of a prevalent intersubtype (C/B') recombinant strain in China. J Virol 74: 11367-11376.
31. Baldwin SL, Shaverdian N, Goto Y, Duthie MS, Raman VS, et al. (2009) Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion. Vaccine 27: 5956-5963.
32. Van Roey GA, Arias MA, Tregoning JS, Rowe G, Shattock RJ, (2012) Thymic stromal lymphopoietin (TSLP) acts as a potent mucosal adjuvant for HIV-1 gp140 vaccination in mice. European Journal of Immunology 42: 353-363.
33. Vila A, Sanchez A, Janes K, Behrens I, Kissel T, et al. (2004) Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice. Eur J Pharm Biopharm 57: 123-131.
34. Arias MA, Loxley A, Eatmon C, Van Roey G, Fairhurst D, et al. (2011) Carnauba wax nanoparticles enhance strong systemic and mucosal cellular and humoral immune responses to HIV-gp140 antigen. Vaccine 29: 1258-1269.
35. Coler RN, Baldwin SL, Shaverdian N, Bertholet S, Reed SJ, et al. (2010) A synthetic adjuvant to enhance and expand immune responses to influenza vaccines. PLoS ONE 5: e13677. 10.1371/journal.pone.0013677 [doi].
36. Pantel A, Cheong C, Dandamudi D, Shrestha E, Mehandru S, et al. (2012) A new synthetic TLR4 agonist, GLA, allows dendritic cells targeted with antigen to elicit Th1 T-cell immunity in vivo. Eur J Immunol 42: 101-109. 10.1002/eji.201141855 [doi].
37. Baldwin SL, Bertholet S, Kahn M, Zharkikh I, Ireton GC, et al. (2009) Intradermal immunization improves protective efficacy of a novel TB vaccine candidate. Vaccine 27: 3063-3071.
38. Baldwin SL, Bertholet S, Reese VA, Ching LK, Reed SG, et al. (2012) The Importance of Adjuvant Formulation in the Development of a Tuberculosis Vaccine. J Immunol. jimmunol.1102696 [pii];10.4049/jimmunol.1102696 [doi].
39. Didierlaurent AM, Morel S, Lockman L, Giannini SL, Bisteau M, et al. (2009) AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol 183: 6186-6197. jimmunol.0901474 [pii];10.4049/jimmunol.0901474 [doi].
40. Baldwin SL, Bertholet S, Reese VA, Ching LK, Reed SG, et al. (2012) The Importance of Adjuvant Formulation in the Development of a Tuberculosis Vaccine. J Immunol.
41. Schneider LP, Schoonderwoerd AJ, Moutaftsi M, Howard RF, Reed SG, et al. (2012) Intradermally administered TLR4 agonist GLA-SE enhances the capacity of human skin DCs to activate T cells and promotes emigration of Langerhans cells. Vaccine. S0264-410X(12)00587-7 [pii];10.1016/j.vaccine.2012.04.051 [doi].
42. Sui Z, Chen Q, Fang F, Zheng M, Chen Z, (2010) Cross-protection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant. Vaccine 28: 7690-7698. S0264-410X(10)01329-0 [pii];10.1016/j.vaccine.2010.09.019 [doi].
43. van der Lubben IM, Verhoef JC, Borchard G, Junginger HE, (2001) Chitosan and its derivatives in mucosal drug and vaccine delivery. European Journal of Pharmaceutical Sciences 14: 201-207.
44. Zaharoff DA, Rogers CJ, Hance KW, Schlom J, Greiner JW, (2007) Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination. Vaccine 25: 2085-2094. S0264-410X(06)01225-4 [pii];10.1016/j.vaccine.2006.11.034 [doi].
45. Lewkowich IP, Herman NS, Schleifer KW, Dance MP, Chen BL, et al. (2005) CD4+CD25+ T cells protect against experimentally induced asthma and alter pulmonary dendritic cell phenotype and function. J Exp Med 202: 1549-1561. jem.20051506 [pii];10.1084/jem.20051506 [doi].
46. Brewer JM, Tetley L, Richmond J, Liew FY, Alexander J, (1998) Lipid vesicle size determines the Th1 or Th2 response to entrapped antigen. J Immunol 161: 4000-4007.
47. Lin Y, Slight SR, Khader SA, (2010) Th17 cytokines and vaccine-induced immunity. Seminars in immunopathology 32: 79-90. 10.1007/s00281-009-0191-2 [doi].
48. Kanwar B, Favre D, McCune JM, (2010) Th17 and regulatory T cells: implications for AIDS pathogenesis. Curr Opin HIV AIDS 5: 151-157. 10.1097/COH.0b013e328335c0c1 [doi];01222929-201003000-00009 [pii].
49. Klatt NR, Brenchley JM, (2010) Th17 cell dynamics in HIV infection. Curr Opin HIV AIDS 5: 135-140. 10.1097/COH.0b013e3283364846 [doi];01222929-201003000-00006 [pii].
50. Guglani L, Khader SA, (2010) Th17 cytokines in mucosal immunity and inflammation. Curr Opin HIV AIDS 5: 120-127. 10.1097/COH.0b013e328335c2f6 [doi];01222929-201003000-00004 [pii].